CY1113290T1 - Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3 - Google Patents
Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3Info
- Publication number
- CY1113290T1 CY1113290T1 CY20121100908T CY121100908T CY1113290T1 CY 1113290 T1 CY1113290 T1 CY 1113290T1 CY 20121100908 T CY20121100908 T CY 20121100908T CY 121100908 T CY121100908 T CY 121100908T CY 1113290 T1 CY1113290 T1 CY 1113290T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mag
- detectors
- diagnosis
- indicator
- cancer detection
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000007858 starting material Substances 0.000 title 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Manufacturing & Machinery (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0612342.6A GB0612342D0 (en) | 2006-06-21 | 2006-06-21 | Method |
| EP07786793A EP2041308B1 (en) | 2006-06-21 | 2007-06-21 | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113290T1 true CY1113290T1 (el) | 2016-04-13 |
Family
ID=36803668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100908T CY1113290T1 (el) | 2006-06-21 | 2012-10-02 | Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8936919B2 (https=) |
| EP (1) | EP2041308B1 (https=) |
| JP (2) | JP2009540812A (https=) |
| KR (1) | KR101455589B1 (https=) |
| CN (1) | CN101506383B (https=) |
| AU (1) | AU2007263019B2 (https=) |
| BR (1) | BRPI0713599A2 (https=) |
| CA (1) | CA2656909A1 (https=) |
| CO (1) | CO6140072A2 (https=) |
| CY (1) | CY1113290T1 (https=) |
| DK (1) | DK2041308T3 (https=) |
| EA (1) | EA016347B1 (https=) |
| ES (1) | ES2389513T3 (https=) |
| GB (1) | GB0612342D0 (https=) |
| HR (1) | HRP20120761T1 (https=) |
| IL (1) | IL195975A (https=) |
| MA (1) | MA30565B1 (https=) |
| MX (1) | MX2008016493A (https=) |
| MY (1) | MY147511A (https=) |
| NO (1) | NO20085290L (https=) |
| NZ (1) | NZ573809A (https=) |
| PL (1) | PL2041308T3 (https=) |
| PT (1) | PT2041308E (https=) |
| SI (1) | SI2041308T1 (https=) |
| UA (1) | UA95956C2 (https=) |
| WO (1) | WO2007147876A2 (https=) |
| ZA (1) | ZA200810695B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008300397A1 (en) | 2007-09-17 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Improved detection of MAGE-A expression |
| JP5883443B2 (ja) * | 2010-07-22 | 2016-03-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規の抗原結合タンパク質 |
| CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612201A (en) * | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
| WO1994003205A1 (en) * | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
| CA2184482A1 (en) * | 1994-03-01 | 1995-09-08 | Etienne De Plaen | Determination of cancerous conditions by mage gene expression |
| US5985571A (en) * | 1998-02-04 | 1999-11-16 | Ludwig Institute For Cancer Research | Method for determining multiple myeloma by assaying for expression of mage genes |
| CZ298364B6 (cs) * | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
| WO2000020445A2 (en) * | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| JP3603138B2 (ja) * | 2000-02-18 | 2004-12-22 | 独立行政法人理化学研究所 | 細胞死抑制タンパク質 |
| US6358679B1 (en) * | 2000-08-24 | 2002-03-19 | Pe Corporation (Ny) | Methods for external controls for nucleic acid amplification |
| US6635425B2 (en) * | 2001-01-05 | 2003-10-21 | Molecular Staging, Inc. | 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms |
| US7771998B2 (en) * | 2001-11-29 | 2010-08-10 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP1572105B1 (en) * | 2002-11-14 | 2011-08-31 | John Wayne Cancer Institute | Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr |
| GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
| US20070231822A1 (en) * | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
-
2006
- 2006-06-21 GB GBGB0612342.6A patent/GB0612342D0/en not_active Ceased
-
2007
- 2007-06-21 PT PT07786793T patent/PT2041308E/pt unknown
- 2007-06-21 US US12/305,742 patent/US8936919B2/en not_active Expired - Fee Related
- 2007-06-21 PL PL07786793T patent/PL2041308T3/pl unknown
- 2007-06-21 CA CA002656909A patent/CA2656909A1/en not_active Abandoned
- 2007-06-21 DK DK07786793.5T patent/DK2041308T3/da active
- 2007-06-21 UA UAA200814634A patent/UA95956C2/uk unknown
- 2007-06-21 WO PCT/EP2007/056219 patent/WO2007147876A2/en not_active Ceased
- 2007-06-21 CN CN2007800309371A patent/CN101506383B/zh not_active Expired - Fee Related
- 2007-06-21 EA EA200802356A patent/EA016347B1/ru not_active IP Right Cessation
- 2007-06-21 HR HRP20120761TT patent/HRP20120761T1/hr unknown
- 2007-06-21 ES ES07786793T patent/ES2389513T3/es active Active
- 2007-06-21 AU AU2007263019A patent/AU2007263019B2/en not_active Ceased
- 2007-06-21 MX MX2008016493A patent/MX2008016493A/es active IP Right Grant
- 2007-06-21 NZ NZ573809A patent/NZ573809A/en not_active IP Right Cessation
- 2007-06-21 SI SI200731011T patent/SI2041308T1/sl unknown
- 2007-06-21 EP EP07786793A patent/EP2041308B1/en not_active Not-in-force
- 2007-06-21 KR KR1020097001326A patent/KR101455589B1/ko not_active Expired - Fee Related
- 2007-06-21 MY MYPI20085210A patent/MY147511A/en unknown
- 2007-06-21 BR BRPI0713599-8A patent/BRPI0713599A2/pt not_active IP Right Cessation
- 2007-06-21 JP JP2009515886A patent/JP2009540812A/ja active Pending
-
2008
- 2008-12-16 IL IL195975A patent/IL195975A/en not_active IP Right Cessation
- 2008-12-18 NO NO20085290A patent/NO20085290L/no not_active Application Discontinuation
- 2008-12-18 ZA ZA2008/10695A patent/ZA200810695B/en unknown
- 2008-12-19 MA MA31490A patent/MA30565B1/fr unknown
- 2008-12-24 CO CO08136749A patent/CO6140072A2/es unknown
-
2012
- 2012-10-02 CY CY20121100908T patent/CY1113290T1/el unknown
- 2012-11-08 JP JP2012245934A patent/JP5705191B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538607A5 (https=) | ||
| EP1810026A4 (en) | B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER | |
| EA200802242A1 (ru) | Способ определения того, будет или не будет пациент респондером на иммунотерапию | |
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| WO2014140933A8 (en) | Method for the prognosis and treatment of cancer metastasis | |
| WO2007109881A8 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
| GB201009641D0 (en) | Methods of monitoring conditions by sequence analysis | |
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| EP4293358A3 (en) | Volatile organic compounds as cancer biomarkers | |
| WO2010027903A8 (en) | Lung cancer diagnosis | |
| EA201370063A1 (ru) | Фосфолипидом рака | |
| CY1116089T1 (el) | Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων | |
| CY1116133T1 (el) | Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| MX2013011431A (es) | Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. | |
| MY184498A (en) | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states | |
| ES2570627T3 (es) | Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal | |
| CY1122202T1 (el) | Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης | |
| SG165370A1 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites | |
| CY1113290T1 (el) | Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3 | |
| EP1924710A4 (en) | METHOD FOR DIAGNOSIS OF AN OVARIAN CARCINOMA AND KIT THEREFOR | |
| MX2021009281A (es) | Metodos de deteccion de legionella. | |
| ES2570609T3 (es) | Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal | |
| EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании |